340B Drug Pricing Program
The exorbitant cost of many prescription drugs threatens providers鈥 ability to provide life-saving medications for millions of Americans.That is why the 340B Drug Pricing Program, which provides discounts on drugs to some health care providers who serve large numbers of low-income and uninsured鈥
The House Energy & Commerce Subcommittee on Oversight and Investigations today held a hearing to review the Health Resources and Services Administration鈥檚 oversight of the 340B Drug Pricing Program and how the program impacts patients, providers, manufacturers and other stakeholders.
The AHA July 13 criticized proposed deep cuts to how much the Centers for Medicare & Medicaid Services reimburses hospitals for drugs acquired under the 340B Drug Pricing Program and proposes changes to site-neutral payment policies under Section 603 of the 2015 Bipartisan Budget Act.
On July 13, the CMS released two calendar year 2018 proposed rules: the outpatient prospective payment system/ambulatory surgical center proposed rule and the Medicare physician fee schedule proposed rule.
The Centers for Medicare & Medicaid Services today proposed to update hospital outpatient prospective payment system rates by 1.75% in calendar year 2018 compared to CY 2017. The rule also would drastically cut Medicare payment for drugs that are acquired under the 340B Drug Pricing鈥
Today, CMS issued several poorly designed policies that will do real damage to patients access to care.
Reps. Peter Welch (D-VT) and Gregg Harper (R-MS) yesterday introduced the Closing Loopholes for Orphan Drugs Act (H.R. 2889, legislation that would limit the 鈥渙rphan drug鈥 exclusion for 340B Drug Pricing Program rural and cancer hospitals.
The skyrocketing price of prescription drugs threatens both patient access to care and the ability of providers to deliver the highest quality of care to patients and communities.
The Health Resources and Services Administration today delayed to Oct. 1 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers. The final rule was subject to multiple delays since January.